NCT00397059View on ClinicalTrials.gov

Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Healthy
Interventions
DRUG

Escitalopram

Trial Locations (1)

DK-5000

Clinical Pharmacology, University of Southern Denmark, Odense

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

University of Southern Denmark

OTHER

NCT00397059 - Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism | Biotech Hunter | Biotech Hunter